Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PYC Therapeutics Limited ( (AU:PYC) ) has issued an announcement.
PYC Therapeutics Limited has issued 2.5 million unlisted employee options under its employee incentive scheme, effective 5 January 2026. The unquoted options are not intended to be listed on the ASX and form part of the company’s broader strategy to retain and incentivise key personnel, signalling continued reliance on equity-based compensation to support its development pipeline and align employees with future growth objectives.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is an Australian biotechnology company listed on the ASX, operating in the therapeutics and life sciences sector. The company focuses on developing novel therapies, with its activities supported in part through equity-based employee incentive structures, aligning staff interests with long-term shareholder value.
Average Trading Volume: 455,044
Technical Sentiment Signal: Buy
Current Market Cap: A$965.3M
For a thorough assessment of PYC stock, go to TipRanks’ Stock Analysis page.